Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
December 8, 2025Blood

A genomic analysis of patients with chronic lymphocytic leukemia treated with fixed duration therapy in a first-line setting in alberta, Canada

View Full Paper
Ask AI
Bookmark
Share

Authors

SGSydney GeorgeMSMariet Mathew Stephen

Discussion

Loading...

Member takes

Overview

Retrospective study finds genomic testing rates are low in CLL patients receiving first-line targeted therapy, suggesting need for improved guidelines adherence.

Key Points

  • Patients treated with targeted therapies had higher genomic testing rates compared to those receiving CIT.
  • A secondary analysis noted 57% of patients in 2022-2023 initiated targeted therapy with venetoclax and obinutuzumab.
  • Genomic testing was completed for 93.5%-100% of patients treated with targeted therapy, contrasted with lower rates for CIT.
  • Despite existing guidelines, significant gaps may hinder optimal treatment selection based on genetic profiling.

Cite This Study

George et al. (2025) studied this question.

synapsesocial.com/papers/69362f5d4fa91c937236dc37https://doi.org/10.1182/blood-2025-8013
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Real-world selection of fixed-duration versus continuous therapies for treatment-naïve chronic lymphocytic leukemia/small lymphocytic lymphoma2025
  2. 2Real-world chronic lymphocytic leukemia (CLL)–specific biomarker testing patterns and frontline treatment patterns in patients with CLL/small lymphocytic lymphoma (SLL)2025
  3. 3Impact of testing for genetic markers on treatment selection and clinical outcomes among patients with chronic lymphocytic leukemia2025
  4. 4An international view on the current approaches to frontline chronic lymphocytic leukemia therapy2025
  5. 5Contemporary Fixed-Duration Treatment Options in the First-Line Setting of Chronic Lymphocytic Leukemia: Perspectives from a Publicly Funded Healthcare System2025 · 3 citations